ArticleJCO precision oncology2022

A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Prior Trastuzumab and Pertuzumab.

Stefanie Fischer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.